Bcl-6与Ki-67在非霍奇金淋巴瘤中的表达及临床意义

Expressions and clinical significances of Bcl-6 and Ki-67 in non-Hodgkin' s lymphoma

目的:研究Bcl-6癌基因和Ki-67抗原在非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)组织中的表达水平及相互关系,评价Bcl-6和Ki-67作为NHL患者预后指标的价值。方法:采用免疫组织化学PV-9000两步法检测Bcl-6和Ki-67抗原在84例NHL肿瘤组织和18例淋巴结反应性增生(reactive hyperplasia of lymph node,RH)组织中的表达水平。结果:Bcl-6、Ki-67在NHL组织中阳性表达率分别为53.57%(45/84)和61.90%(52/84),与淋巴结反应性增生组比较差异有统计学意义(P<0.05)。Bcl-6的表达与临床分期、免疫分型及血清乳酸脱氢酶水平有关(P<0.05),Ki-67的表达与恶性程度、临床分期、血清乳酸脱氢酶水平及近期疗效有关(P<0.05)。Bcl-6与Ki-67表达无相关性(X^2=0.955,P>0.05)。结论:Bcl-6与Ki-67的异常表达与NHL临床分期及血清乳酸脱氢酶水平有关,两者与NHL的发生、发展有关,并可为预后判断提供参考依据。

Objective： To study expressions and correlations of Bcl-6 and Ki-67 in non-Hodgkin＇s lymphoma （NHL） and the evaluation as prognostic indicator of NHL. Methods： Bel 6 and Ki-67 expressions were detected in the tissues of 84 patients with NHL as well as 18 reactive hyperplasia of lymphnode by immunohistoehemistry （PV 9000 method）. Results： Positive expression rates of Bcl-6 and Ki-67 in NHL were 53.57% and 61.90%. Positive expression rates of Bcl-6 and Ki 67 in NHL were higher than that in reactive hyperplasia of lymphnode （P〈0.05）. There were correlations between Bel-6 expression and Ann-Arbor clinical stage, immunophenotyping or LDH （P〈0. 05）. There were correlations between Ki-67 expression and tumor histopathologic classification, Ann-Arbor clinical stage, LDH or recent effect （P〈 0.05）. There was no correlation between the expression of Bcl-6 and Ki-67 in NHL （X^2 =0. 955, P 0.05）. Conclusion： There was correlation between expression of Bcl-6 and Ki-67 in NHL and Ann-Arbor clinical stage or LDH. The occurrence and development of NHL may be related with expressions ol Bcl-6 protein and Ki-67. They could be ehoosen as predictors of prognosis in NHL.